Die Ophthalmologie · 2026
[Real-world experience with aflibercept 8 mg for treatment of neovascular age-related macular degeneration after 12 months].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Grün Michael, Rothaus Kai, Beger Alexander, Winter Carla, Lommatzsch Albrecht, Faatz Henrik
Аннотация
BACKGROUND: The phase 3 clinical trial PULSAR demonstrated extended treatment intervals with aflibercept 8 mg in treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) in a large proportion of the cohort, with good drug safety. Early clinical experience in real-world settings confirmed the efficacy in both treatment-naïve and pretreated patients but no data on longer observation periods are available yet.
OBJECTIVE: The aim of the study was to investigate the efficacy, treatment frequency and tolerability of aflibercept 8 mg over a period of 12 months in a group of pretreated nAMD patients.
MATERIAL AND METHODS: A retrospective study of 73 eyes with nAMD and pretreatment with anti-VEGF switched to aflibercept 8 mg. Eyes were initially uploaded with 3 monthly intravitreal injections (IVI), followed by a pro re nata (PRN) regimen. Outcome parameters included visual acuity development and central retinal thickness (CSRT) after upload and 12 months, treatment frequency in the year before and after switching to aflibercept 8 mg, and the overall tolerability of the drug.
RESULTS: Of the initial 73 eyes, 27 eyes (37.0%) were still receiving aflibercept 8 mg after 12 months. In these eyes CSRT was reduced from 387.9 ± 138.4 µm initially to 305.5 ± 93.2 µm after upload and 328.9 ± 105.6 µm after 12 months (p < 0.001). Visual acuity remained stable (p > 0.05). Compared to the year prior to switching, the injection frequency was reduced from 8.2 ± 2.1 to 6.9 ± 1.0 IVIs (p < 0.005). During the observation period, a total of 5 eyes (6.8%) developed noninfectious intraocular inflammation (IOI), with all cases completely regressing with topical treatment.
CONCLUSION: These results confirm a good efficacy of aflibercept 8 mg for the treatment of nAMD with reduced injection frequency after 12 months of treatment in a portion of pretreated eyes that were often previously refractory to treatment. Longer observation intervals and experience with other treatment regimens are necessary to confirm this observation.
OBJECTIVE: The aim of the study was to investigate the efficacy, treatment frequency and tolerability of aflibercept 8 mg over a period of 12 months in a group of pretreated nAMD patients.
MATERIAL AND METHODS: A retrospective study of 73 eyes with nAMD and pretreatment with anti-VEGF switched to aflibercept 8 mg. Eyes were initially uploaded with 3 monthly intravitreal injections (IVI), followed by a pro re nata (PRN) regimen. Outcome parameters included visual acuity development and central retinal thickness (CSRT) after upload and 12 months, treatment frequency in the year before and after switching to aflibercept 8 mg, and the overall tolerability of the drug.
RESULTS: Of the initial 73 eyes, 27 eyes (37.0%) were still receiving aflibercept 8 mg after 12 months. In these eyes CSRT was reduced from 387.9 ± 138.4 µm initially to 305.5 ± 93.2 µm after upload and 328.9 ± 105.6 µm after 12 months (p < 0.001). Visual acuity remained stable (p > 0.05). Compared to the year prior to switching, the injection frequency was reduced from 8.2 ± 2.1 to 6.9 ± 1.0 IVIs (p < 0.005). During the observation period, a total of 5 eyes (6.8%) developed noninfectious intraocular inflammation (IOI), with all cases completely regressing with topical treatment.
CONCLUSION: These results confirm a good efficacy of aflibercept 8 mg for the treatment of nAMD with reduced injection frequency after 12 months of treatment in a portion of pretreated eyes that were often previously refractory to treatment. Longer observation intervals and experience with other treatment regimens are necessary to confirm this observation.